Anti-EGFR antibodies (cetuximab and panitumumab) have improved outcomes in patients with RAS wild-type advanced CRC [9,10], whereas activating mutations in KRAS or NRAS, present in 52% of metastatic CRC [11], provide resistance to anti-EGFR therapies, as the downstream activation of the signaling pathway is independent of EGFR. The gene discussed is KRAS; the disease is colorectal carcinoma.